Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer)
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer)
Sponsor: DexCom, Inc.
A PHASE3 clinical study on Type1 Diabetes, this trial is completed. The trial is conducted by DexCom, Inc. and has accumulated 15 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Dec 2024 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Dec 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 10 earlier versions
-
Nov 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Sep 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE3
-
May 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2020 — May 2020 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- DexCom, Inc.
- Jaeb Center for Health Research
- Juvenile Diabetes Research Foundation
- Medtronic
- Tandem Diabetes Care, Inc.
- University of Minnesota
For direct contact, visit the study record on ClinicalTrials.gov .